ABSI is trading 5% down at $11.01 as the stock undergoes consolidation following a significant multi-day run-up.
- The pullback follows a period of intense optimism surrounding the company's AI-enabled drug discovery platform and strong-buy sentiment from analysts.
- With no fresh company-specific news or earnings reports released today, the decline appears to be driven by profit-taking after steep gains since late June.
- The stock's movement comes amid a largely flat broader market, highlighting a localized correction for the biotech firm.